Stock 600721 XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd

Equities

600721

CNE000000KQ1

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
5.7 CNY +3.83% Intraday chart for Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd +11.11% -26.36%
Apr. 25 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 25 Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,102 2,562 1,459 2,810 2,311 2,949
Enterprise Value (EV) 1 1,979 2,486 1,404 2,729 2,178 2,748
P/E ratio -2.6 x 74.4 x -4.74 x 47 x -66.4 x 226 x
Yield - - - - - -
Capitalization / Revenue 5.01 x 9.78 x 17.3 x 9.99 x 6.61 x 7.98 x
EV / Revenue 4.72 x 9.49 x 16.6 x 9.7 x 6.22 x 7.44 x
EV / EBITDA 14.9 x 39.9 x -7.28 x 70.2 x -297 x 30.5 x
EV / FCF -270 x -85.6 x 21.7 x -110 x 33.2 x 35.5 x
FCF Yield -0.37% -1.17% 4.61% -0.91% 3.01% 2.81%
Price to Book 2.3 x 2.68 x 2.36 x 4.12 x 3.48 x 4.2 x
Nbr of stocks (in thousands) 400,386 400,386 375,134 375,134 376,403 380,951
Reference price 2 5.250 6.400 3.890 7.490 6.140 7.740
Announcement Date 4/28/19 4/21/20 3/30/21 3/29/22 4/11/23 4/25/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 419.2 262 84.53 281.4 349.9 369.3
EBITDA 1 132.8 62.34 -192.9 38.88 -7.336 90.02
EBIT 1 106.2 32.61 -221.9 14.04 -32.71 68.75
Operating Margin 25.33% 12.45% -262.55% 4.99% -9.35% 18.62%
Earnings before Tax (EBT) 1 -791.7 42.07 -315.7 62.18 -32.12 16.48
Net income 1 -807.9 34.38 -319.8 59.83 -34.75 12.97
Net margin -192.72% 13.12% -378.28% 21.26% -9.93% 3.51%
EPS 2 -2.018 0.0860 -0.8202 0.1595 -0.0925 0.0342
Free Cash Flow 1 -7.335 -29.05 64.69 -24.76 65.6 77.31
FCF margin -1.75% -11.09% 76.53% -8.8% 18.75% 20.94%
FCF Conversion (EBITDA) - - - - - 85.88%
FCF Conversion (Net income) - - - - - 595.97%
Dividend per Share - - - - - -
Announcement Date 4/28/19 4/21/20 3/30/21 3/29/22 4/11/23 4/25/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 123 76.1 55.6 80.6 133 200
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -7.33 -29.1 64.7 -24.8 65.6 77.3
ROE (net income / shareholders' equity) -61.3% 3.6% -40.5% 9.14% -5.13% 1.89%
ROA (Net income/ Total Assets) 4.04% 1.61% -12.2% 0.9% -2.06% 4.16%
Assets 1 -19,972 2,142 2,612 6,673 1,686 311.5
Book Value Per Share 2 2.280 2.380 1.650 1.820 1.770 1.840
Cash Flow per Share 2 0.2500 0.1300 0.1200 0.2300 0.3600 0.5300
Capex 1 56 25.8 3.77 6.04 2.41 17.2
Capex / Sales 13.37% 9.86% 4.46% 2.15% 0.69% 4.67%
Announcement Date 4/28/19 4/21/20 3/30/21 3/29/22 4/11/23 4/25/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD Stock Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd
-26.36% 300M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 600721 Stock
  4. Financials Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd